MedTrace Logo

Liposomal Bupivacaine for Postoperative Pain Control in Urologic Procedures

NCT02805504 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 136

Last updated 2024-04-24

Study results available
· View outcomes & findings →

Summary

A prospective, randomized controlled study to determine the efficacy of liposomal bupivacaine given by local injection at all the wound sites in patients undergoing urologic surgeries.

Conditions

  • Urinary Tract Diseases

Interventions

DRUG

Exparel

This group will receive intraoperative local Liposomal Bupivacaine injection at the surgical site.

DRUG

Marcaine

This group will receive intraoperative Bupivacaine HCl injection at the surgical site.

Sponsors & Collaborators

  • Loma Linda University

    lead OTHER

Principal Investigators

  • Mohamed Keheila, MD · Loma Linda University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-11
Primary Completion
2022-05-09
Completion
2022-05-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02805504 on ClinicalTrials.gov